zurück

Eladocagene exuparvovec (aromatic L-amino acid decarboxylase (AADC) deficiency, patients aged ≥ 18 months)

Subject:

  • Active Sustance: Eladocagene exuparvovec
  • Name: Upstaza®
  • Therapeutic area: L-amino acid decarboxylase (AADC) deficiency
  • Pharmaceutical company: PTC Therapeutics International Limited

 

Time table:

  • Start: 15.08.2022
  • Publication of assessment: 15.11.2022
  • End of public hearing: 06.12.2022
  • Final decision by G-BA: beginning of February 2023

 

Comparative therapy:

  • No comparative therapy due to orphan drug designation